Dylan Dupuis

Stock Analyst at Roth MKM

(2.78)
# 1,994
Out of 5,044 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Dylan Dupuis

Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $3.09
Upside: +806.15%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $4.16
Upside: +164.42%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $8.02
Upside: +186.78%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $35.22
Upside: -9.14%